Coincheck Reports Financial Results for First Quarter of Year Ending March 31, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Should l Buy CNCK?
Source: Newsfilter
Financial Performance Overview: Coincheck Group reported a 12% year-over-year increase in total revenue for Q1 fiscal 2026, totaling ¥84.0 billion ($583 million), but experienced a significant 27% decrease compared to the previous quarter. The company also recorded a net loss of ¥1,377 million ($9.5 million) for the quarter.
Operational Developments: The company launched "Coincheck Staking" to allow users to earn Ethereum rewards and formed a strategic partnership with Mercoin to expand its customer base. Additionally, verified accounts increased by 14% year-over-year, while marketplace trading volume decreased by 16%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNCK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNCK
Wall Street analysts forecast CNCK stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
3.50
Averages
4.25
High
5.00
Current: 2.520
Low
3.50
Averages
4.25
High
5.00
About CNCK
Coincheck Group N.V. is a Netherlands based public limited liability company. Company operates as a holding company of Coincheck, Inc. Coincheck is involved in crypto exchange industry, providing Marketplace and Exchange platforms on which diverse cryptocurrencies, including Bitcoin and Ethereum, are held and exchanged, and offers other retail-focused crypto services. Company derive its total revenue from trading on its Marketplace platform business. Company support trading in 30 different types of cryptocurrencies across its Marketplace and Exchange platforms. Company operates in the crypto asset and Web3 domains.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coincheck Reports Q3 Revenue of $915 Million
- Revenue and Margin Changes: Coincheck reported Q3 revenue of $915 million, with a gross margin decrease of 1% to ¥3,833 million ($24.4 million), indicating competitive pressures despite an increase in IEO revenue that partially offset the decline.
- Significant Drop in Customer Assets: As of December 31, 2025, customer assets fell by 20% to ¥948.5 billion ($6,049 million), primarily due to the market price decline of crypto assets like Bitcoin, Ethereum, and XRP, reflecting the direct impact of market volatility on customer investments.
- User Account Growth: The number of verified accounts increased by 2% to 2,475,345, demonstrating stability in user growth for Coincheck, even as overall asset values declined, indicating sustained user trust in the platform.
- Net Income Increase: Q3 net income rose by 14% to ¥405 million ($2.6 million), driven by a decrease in income tax expenses and an increase in gains from changes in fair value of warrant liabilities, showcasing improvements in cost control and financial management.
See More
Coincheck Group N.V. Reports 16.6% Revenue Growth in Q3
- Revenue Growth: Coincheck Group N.V. reported Q3 revenue of ¥143.5 billion, reflecting a 16.6% year-over-year increase, indicating strong performance in the cryptocurrency market and further solidifying its market position.
- Net Income Performance: The company posted a net income of ¥405 million, showcasing sustained improvement in profitability, which suggests effective cost control and enhanced operational efficiency in a competitive environment.
- M&A Activity: Coincheck announced an all-stock acquisition of 3iQ, aimed at bolstering its asset management capabilities and addressing prior market concerns, which is expected to drive future growth.
- Market Attention: The latest transaction activities by Coincheck have garnered significant market attention, particularly in the context of mergers with companies like Merck and Glencore, highlighting its proactive involvement in industry consolidation.
See More
Coincheck Group Reports Q3 Results and CEO Transition
- Financial Recovery: Coincheck Group reported total revenue of ¥143,455 million (approximately $914.9 million) for Q3 FY2025, reflecting a 16.5% year-over-year increase, indicating a recovery in the crypto market that is likely to boost investor confidence.
- Executive Transition: CEO Gary Simanson announced his resignation effective March 31, 2026, with Chief Growth Officer Pascal St-Jean set to take over, signaling a strategic shift towards expanding the company's institutional presence in the crypto sector.
- Acquisition Strategy: The company announced its acquisition of 3iQ in January 2026, which is expected to enhance its competitive edge in digital asset investment solutions, further solidifying its global market positioning.
- Market Leadership: Coincheck has maintained its position as the top crypto trading app in Japan for seven consecutive years, demonstrating its strong market influence and potential for continued business growth leveraging this advantage.
See More
WD-40 Co Reports Q1 Earnings Miss, Shares Drop 9.1%
- Earnings Decline: WD-40 Co reported Q1 earnings of $1.28 per share, missing the analyst consensus of $1.36, indicating pressure on profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales of $154.423 million fell short of the expected $155.085 million, reflecting weak market demand that may lead to further performance declines.
- Stock Reaction: Following the disappointing results, WD-40 shares dropped 9.1% to $185.00 in pre-market trading, highlighting market concerns regarding the company's financial health.
- Industry Impact: The poor performance of WD-40 may trigger a ripple effect across the industry, prompting investors to reassess the financial health of similar companies, potentially leading to a broader market sentiment downturn.
See More
NASDAQ 100 Pre-Market Indicator Falls, ACRV Trades Over 23 Million Shares
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator decreased by 4.3 points to 25,649.6, indicating weakened market sentiment that could impact investor confidence and lead to increased volatility in the short term.
- ACRV Trading Activity: Acrivon Therapeutics, Inc. (ACRV) saw a pre-market trading volume of 23,307,591 shares, with a price drop of $0.06 to $2.89, reflecting high market interest but potential short-term pressure on the stock.
- TSLA and TQQQ Performance: Direxion Daily TSLA Bull 2X Shares (TSLL) and ProShares UltraPro QQQ (TQQQ) fell by $0.27 and $0.17 respectively, despite TQQQ's 214.29% increase from its 52-week low, indicating ongoing market uncertainty.
- VTYX and NVDA Recommendations: Ventyx Biosciences, Inc. (VTYX) and NVIDIA Corporation (NVDA) are both rated within the 'buy range', trading 2,195,689 shares and 2,158,778 shares respectively, demonstrating sustained investor interest in tech stocks.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
Coincheck Reports Q3 Revenue of $915 Million
- Revenue and Margin Changes: Coincheck reported Q3 revenue of $915 million, with a gross margin decrease of 1% to ¥3,833 million ($24.4 million), indicating competitive pressures despite an increase in IEO revenue that partially offset the decline.
- Significant Drop in Customer Assets: As of December 31, 2025, customer assets fell by 20% to ¥948.5 billion ($6,049 million), primarily due to the market price decline of crypto assets like Bitcoin, Ethereum, and XRP, reflecting the direct impact of market volatility on customer investments.
- User Account Growth: The number of verified accounts increased by 2% to 2,475,345, demonstrating stability in user growth for Coincheck, even as overall asset values declined, indicating sustained user trust in the platform.
- Net Income Increase: Q3 net income rose by 14% to ¥405 million ($2.6 million), driven by a decrease in income tax expenses and an increase in gains from changes in fair value of warrant liabilities, showcasing improvements in cost control and financial management.
See More
Coincheck Group N.V. Reports 16.6% Revenue Growth in Q3
- Revenue Growth: Coincheck Group N.V. reported Q3 revenue of ¥143.5 billion, reflecting a 16.6% year-over-year increase, indicating strong performance in the cryptocurrency market and further solidifying its market position.
- Net Income Performance: The company posted a net income of ¥405 million, showcasing sustained improvement in profitability, which suggests effective cost control and enhanced operational efficiency in a competitive environment.
- M&A Activity: Coincheck announced an all-stock acquisition of 3iQ, aimed at bolstering its asset management capabilities and addressing prior market concerns, which is expected to drive future growth.
- Market Attention: The latest transaction activities by Coincheck have garnered significant market attention, particularly in the context of mergers with companies like Merck and Glencore, highlighting its proactive involvement in industry consolidation.
See More
Coincheck Group Reports Q3 Results and CEO Transition
- Financial Recovery: Coincheck Group reported total revenue of ¥143,455 million (approximately $914.9 million) for Q3 FY2025, reflecting a 16.5% year-over-year increase, indicating a recovery in the crypto market that is likely to boost investor confidence.
- Executive Transition: CEO Gary Simanson announced his resignation effective March 31, 2026, with Chief Growth Officer Pascal St-Jean set to take over, signaling a strategic shift towards expanding the company's institutional presence in the crypto sector.
- Acquisition Strategy: The company announced its acquisition of 3iQ in January 2026, which is expected to enhance its competitive edge in digital asset investment solutions, further solidifying its global market positioning.
- Market Leadership: Coincheck has maintained its position as the top crypto trading app in Japan for seven consecutive years, demonstrating its strong market influence and potential for continued business growth leveraging this advantage.
See More
WD-40 Co Reports Q1 Earnings Miss, Shares Drop 9.1%
- Earnings Decline: WD-40 Co reported Q1 earnings of $1.28 per share, missing the analyst consensus of $1.36, indicating pressure on profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales of $154.423 million fell short of the expected $155.085 million, reflecting weak market demand that may lead to further performance declines.
- Stock Reaction: Following the disappointing results, WD-40 shares dropped 9.1% to $185.00 in pre-market trading, highlighting market concerns regarding the company's financial health.
- Industry Impact: The poor performance of WD-40 may trigger a ripple effect across the industry, prompting investors to reassess the financial health of similar companies, potentially leading to a broader market sentiment downturn.
See More
NASDAQ 100 Pre-Market Indicator Falls, ACRV Trades Over 23 Million Shares
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator decreased by 4.3 points to 25,649.6, indicating weakened market sentiment that could impact investor confidence and lead to increased volatility in the short term.
- ACRV Trading Activity: Acrivon Therapeutics, Inc. (ACRV) saw a pre-market trading volume of 23,307,591 shares, with a price drop of $0.06 to $2.89, reflecting high market interest but potential short-term pressure on the stock.
- TSLA and TQQQ Performance: Direxion Daily TSLA Bull 2X Shares (TSLL) and ProShares UltraPro QQQ (TQQQ) fell by $0.27 and $0.17 respectively, despite TQQQ's 214.29% increase from its 52-week low, indicating ongoing market uncertainty.
- VTYX and NVDA Recommendations: Ventyx Biosciences, Inc. (VTYX) and NVIDIA Corporation (NVDA) are both rated within the 'buy range', trading 2,195,689 shares and 2,158,778 shares respectively, demonstrating sustained investor interest in tech stocks.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
